You are here
Open
NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.
If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).
-
RFA-MD-23-003: Innovations for Healthy Living- Improving Minority Health and Eliminating Health Disparities (R43/R44- Clinical Trial Optional)
Release Date: 01-30-2023Open Date: 02-24-2023 Due Dates: Multiple Close Date: 09-07-2023Despite continued improvement in the health of the U.S. population with the introduction of medical and scientific advances, there continues to be an alarming disproportionate burden of illness among certain population groups. The mission of the NIMHD is to lead scientific research aimed at the development of innovative diagnostics, treatments, and prevention strategies to improve minority health ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
75N91023R00034: National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2024
Release Date: 03-13-2023Open Date: 03-13-2023Due Date: 08-22-2023Close Date: 09-06-2023The National Cancer Institute is soliciting proposals from small business concerns to perform key activities to demonstrate technical feasibility and proof-of-concept for the development of highly innovative and potentially transformative technologies in the following areas: Development of therapeutic technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers. Development o ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-TR-22-032: Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) (U43/U44- Clinical Trail Not Allowed)
Release Date: 09-19-2022Open Date: 10-21-2022 Due Dates: Multiple Close Date: 08-22-2023Section I. Funding Opportunity Description This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR)Phase I and Phase II (Fast track and Direct to phase II) grant applications. The funding opportunity will utilize a U43/U44 cooperative agreement to support small business concerns (SBCs) to propose a ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-TR-22-031: Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) (UT1, UT2 Clinical Trail Not Allowed)
Release Date: 09-19-2022Open Date: 10-20-2022 Due Dates: Multiple Close Date: 08-22-2023This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR)Phase I and Phase II (no Direct to Phase II allowed) grant applications. The funding opportunity will utilize a UT1/UT2 cooperative agreement to support small business concerns (SBCs) to propose applications for the qualification of neuromuscu ...
STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-ES-23-005: SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
Release Date: 03-03-2023Open Date: 06-14-2023Due Date: 07-14-2023Close Date: 07-15-2023This SBIR Funding Opportunity Announcement (FOA) focuses on the development of e-Learning health and safety training products from a variety of delivery methods to assist both students and instructors in the training and education process. Note that all products must be directly related to the health and safety training of workers exposed to hazardous materials (HAZMAT). Workers that may be expose ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-TR-22-029: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)
Release Date: 07-13-2022Open Date: 07-18-2022 Due Dates: Multiple Close Date: 07-13-2023A. Overview While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underlie multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molec ...
SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health -
PAR-21-247: Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial Not Allowed)
Release Date: 07-09-2021Open Date: 10-01-2021 Due Dates: Multiple Close Date: 06-16-2023Purpose This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to accelerate innovation and early development in the emerging field of single-molecule protein sequencing (SMPS). This FOA is seeking novel technologies or significant improvements to existing technologies. Exploration of technologies other than those currently being commercialized is highly encouraged. The s ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
PAR-20-111: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
Release Date: 03-02-2020Open Date: 07-11-2020 Due Dates: Multiple Close Date: 05-08-2023A. Overview Recent advances in neuroscience offer unprecedented opportunities to discover new treatments for nervous system disorders. However, before a new chemical entity can be tested in a clinical setting, it must undergo a process of chemical optimization to improve potency, selectivity, and drug-like properties, followed by pre-clinical safety testing to meet the standards set by the Food a ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
PA-22-176: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
Release Date: 06-02-2022Open Date: 08-05-2022 Due Dates: Multiple Close Date: 04-06-2023The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, also known as America's Seed Fund, are one of the largest sources of early-stage capital for technology commercialization in the United States. These programs enable US-owned and operated small businesses to conduct research and development that has a strong potential for commercialization. Nation ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
PA-22-177: PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
Release Date: 06-02-2022Open Date: 08-05-2022 Due Dates: Multiple Close Date: 04-06-2023The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, also known as America's Seed Fund, are one of the largest sources of early-stage capital for technology commercialization in the United States. These programs enable US-owned and operated small businesses to conduct research and development that has a strong potential for commercialization. Nation ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health